Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Assessing gait and balance in rare neurological diseases

Official title: Gait and Balance Impairment in Rare and Very Rare Neurological Diseases

Run by Istituto Auxologico Italiano · NCT06343558 · Data updated 2026-11-12

This study looks at how walking and balance are affected in people with rare neurological diseases to better understand their challenges and risks of falling.

More Multiple Sclerosis trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment200 (estimated)
SponsorIstituto Auxologico Italiano
Academic / other
Locations2 sites (Milan, Milan and 1 other locations)
StatusRecruiting
StartedMay 30, 2023
Main results expectedMay 1, 2027
Study endsMay 1, 2027
Registry record updatedAugust 3, 2025
Trial IDNCT06343558 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults over 18 with multiple sclerosis, Parkinson's disease, peripheral neuropathy, or other rare neurological conditions.

Probably not a fit

Patients with conditions affecting balance and gait due to other medical issues, such as lower limb amputation or recent major orthopedic surgery, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on individuals with rare and very rare neurological diseases, including conditions like multiple sclerosis and Parkinson's disease. It aims to evaluate gait and balance impairments that are common in these conditions, which can lead to increased fall risk and injuries. Participants will undergo assessments using questionnaires, clinical scales, and instrumental tests to gather essential data on their motor functions. The study seeks to improve understanding of these diseases, which are often poorly characterized due to their rarity.

Why it matters

Potential benefit: If successful, this study could enhance diagnosis and treatment strategies for patients with rare neurological diseases.

How similar studies have gone: While there are few studies on rare neurological diseases, existing research has shown that understanding gait and balance can lead to better management of these conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria

* Multiple sclerosis, Parkinson's disease, peripheral neuropathy of the lower limbs or rare or ultrarare neurological disease (e.g. la Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome - CANVAS, ORPHAcode: 504476; Wilson's disease, ORPHAcode: 905)
* undiagnosed neurological disease, i.e. a neurological disease that remains unknown after a full diagnostic assessment;
* age \> 18 years;
* ability to stand upright with no assistance and no assistive device for \> 30 seconds;
* ability to walk without assistance and with no assistive device for \> 50 m;
* ability to give their informed consent.

Exclusion criteria

* pregnancy or breastfeeding
* any other medical conditions affecting by itself balance and gait (e.g. lower limb amputation, hemiparesis due to a stroke)
* major orthopaedic surgery (e.g. hip or knee replacement).

Where it's running

  • IRCCS Istituto Auxologico Italiano
    Milan, Milan, Italy
    Recruiting
  • IRCCS Istituto Neurologico Carlo Besta
    Milan, Italy
    Active not recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.